Search

for
Search:

Did you mean 5-alpha-reductase inhibitor?

Glossary5-alpha-reductase inhibitor

blocks enzyme converting testosterone to dihydrotestosterone (DHT)

A 5-alpha-reductase inhibitor is a type of medication that blocks the enzyme 5-alpha-reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). By reducing DHT levels, these inhibitors can help treat conditions like male pattern baldness and benign prostatic hyperplasia (BPH).

Related Terms

Sort by

Research

30 / 1000+ results

research Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate: An In Vitro and In Silico Approach

12 citations , November 2024 in “Plants”

Phytosterols may help manage prostate issues but are less effective than synthetic drugs.

research FRI-02 FROM GIRLS TO BOYS TO OLDER MEN, THE INTERESTING TALE OF THE GUEVEDOCES AND 5-ALPHA REDUCTASE INHIBITORS

March 2016 in “The Journal of Urology”

The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.

research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors

August 2024 in “Research Square (Research Square)”

Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.

research The risk of dementia with the use of 5 alpha reductase inhibitors

18 citations , June 2017 in “Journal of the neurological sciences”

Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.

research The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson’s disease

15 citations , January 2017 in “Experimental Neurology”

Finasteride reduces movement issues in Parkinson's disease rats.

research Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?

9 citations , August 2019 in “Clinical genitourinary cancer”

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study

6 citations , September 2024 in “Journal of the American Academy of Dermatology”

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double-Blind Placebo-Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

research 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

5 citations , November 2020 in “medRxiv (Cold Spring Harbor Laboratory)”

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

research Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis

4 citations , May 2019 in “The World Journal of Men's Health”

Taking 5 alpha reductase inhibitor medication slightly increases the risk of depression, especially as you get older.

research 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis

4 citations , October 2018 in “International Braz J Urol”

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

research Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.

3 citations , August 2020 in “Urology Journal”

Using 5-alpha reductase inhibitors may increase the risk of mild depression.

research Bladder cancer survival in men using 5-alpha-reductase inhibitors

3 citations , March 2018 in “European Urology Supplements”

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

research No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study

April 2026 in “Journal of the American Academy of Dermatology”

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.

research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study

January 2026 in “Yonsei Medical Journal”

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know

November 2024 in “Journal of Family Medicine and Primary Care”

5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.

research Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia

November 2023 in “Expert Opinion on Pharmacotherapy”

Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.

research An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications

July 2025 in “American Journal on Addictions”

Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.

research Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study.

1 citations , October 2022 in “Iet Nanobiotechnology”

The dutasteride nanoemulsion could improve hair loss treatment by enhancing drug penetration and retention in hair follicles.

research Comparative Efficacy of Oral and Topical 5-Alpha Reductase Inhibitors in Reducing Dihydrotestosterone levels across Men with Androgenetic Alopecia: A Network Meta-Analysis incorporating Post-Hoc Analyses of Randomized Clinical Trial Data

January 2026 in “Open Science Framework”

Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.

pH Stimulus-Responsive Hybrid Nanoparticles: A System Designed for Follicular Delivery of Brazilian Plant-Derived 5-Alpha-Reductase Enzyme Inhibitors

research pH STIMULUS-RESPONSIVE HYBRID NANOPARTICLES: A SYSTEM DESIGNED FOR FOLLICULAR DELIVERY OF BRAZILIAN PLANT-DERIVED 5-ALPHA-REDUCTASE ENZYME INHIBITORS

December 2023 in “International Journal of Pharmaceutics”

New nanoparticles deliver plant extracts to hair follicles to treat conditions like hair loss and acne.

Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study

research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study

February 2026 in “Mendeley Data”

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study

November 2025 in “Mendeley Data”

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

The Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Scalp Skin Testosterone and Dihydrotestosterone Concentrations in Patients with Male Pattern Baldness

research The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.

59 citations , September 1994 in “The Journal of Clinical Endocrinology and Metabolism”

Finasteride reduces scalp DHT levels, potentially treating male pattern baldness.

In Search of Predictive Models for Inhibitors of 5-Alpha Reductase 2 Based on the Integration of Bioactivity and Molecular Descriptors Data

research In Search of Predictive Models for Inhibitors of 5-alpha Reductase 2 Based on the Integration of Bioactivity and Molecular Descriptors Data.

January 2014 in “IWBBIO”

The models can help find better inhibitors for conditions like baldness and prostate disorders.

Intraethnic Variation in Steroid-5-Alpha-Reductase Polymorphisms in Prostate Cancer Patients: A Potential Factor Implicated in 5-Alpha-Reductase Inhibitor Treatment

research Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment

4 citations , June 2015 in “Journal of Genetics/Journal of genetics”

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Effects of 5-Alpha Reductase Inhibitors on Erectile Function, Sexual Desire, and Ejaculation

research Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.

22 citations , September 1994 in “The Journal of Clinical Endocrinology and Metabolism”

Finasteride reduces dihydrotestosterone, increases testosterone, and may treat hirsutism in women.

research Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia

19 citations , January 2016 in “Annals of Dermatology”

Dutasteride is safe and effective for treating hair loss, but may decrease libido.

Search

for
Search:

Related Terms

Research

research Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate: An In Vitro and In Silico Approach

research FRI-02 FROM GIRLS TO BOYS TO OLDER MEN, THE INTERESTING TALE OF THE GUEVEDOCES AND 5-ALPHA REDUCTASE INHIBITORS

research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors

research The risk of dementia with the use of 5 alpha reductase inhibitors

research The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson’s disease

research Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?

research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study

research 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

research Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis

research 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis

research Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.

research Bladder cancer survival in men using 5-alpha-reductase inhibitors

research No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study

research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study

research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know

research Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia

research An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications

research Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study.

research Comparative Efficacy of Oral and Topical 5-Alpha Reductase Inhibitors in Reducing Dihydrotestosterone levels across Men with Androgenetic Alopecia: A Network Meta-Analysis incorporating Post-Hoc Analyses of Randomized Clinical Trial Data

research pH STIMULUS-RESPONSIVE HYBRID NANOPARTICLES: A SYSTEM DESIGNED FOR FOLLICULAR DELIVERY OF BRAZILIAN PLANT-DERIVED 5-ALPHA-REDUCTASE ENZYME INHIBITORS

research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study

research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study

research The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.

research In Search of Predictive Models for Inhibitors of 5-alpha Reductase 2 Based on the Integration of Bioactivity and Molecular Descriptors Data.

research Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment

research Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation

research Side Effects of 5‐Alpha Reductase Inhibitors: A Comprehensive Review

research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.

research Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.

research Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia